Biological therapy of allergic diseases during the COVID-19 pandemic

ABSTRACT

The outbreak of the SARS-CoV-2-induced Coronavirus Disease 2019 (COVID-19) pandemic started in December 2019 in Wuhan, China, continued to spread across the globe and spanned 188 countries. Under the new circumstances treatment approach for T2 allergic diseases such as asthma, chronic hives, atopic dermatitis, and sinusitis with polyps has been changed. In the past years, new biological therapies – monoclonal antibodies for these diseases have been developed targeting different aspects of the type 2 immune response. New knowledge on the COVID-19 disease course raises many issues around the safety of biologicals in patients with active infection, as well as their interactions with antiviral medications. In Russia new biological therapies entered clinical practice but it's effectiveness and safety still are not known. This newsletter is based on "Considerations on Biologicals for Patients with allergic disease in times of the COVID-19 pandemic an EAACI Statement” and the latest scientific data. © 2020 Pharmarus Print Media License CC BY-NC-ND.